More treatment choices does not always mean better patient outcomes, with care access remaining challenging in Florida.
|Articles|October 1, 2012
Roche's Breast Cancer Franchise Boosted by Trial Data
Advertisement
Roche, the world's biggest maker of cancer drugs, got a boost on Monday as results of trials that will protect sales of its breast cancer drug Herceptin coincided with data showing a new drug in the franchise helped patients live longer.
Two trials on Roche's blockbuster Herceptin wiped out a risk that they could have indicated a shorter period of treatment than the current recommendation of one year - a finding that could have cost up to $1.5 billion in sales.
Read the full story:
Source: Oncology Business Review
Advertisement
Related to this article
Oncologists weighted how to choose, manage, and deliver new therapeutics beyond major academic centers.
Financial toxicity affects nearly half of adults with sarcoma in a US cohort, and the authors call for routine screening to guide targeted support.
The NCCN’s latest esophageal/EGJ guidance raises durvalumab plus FLOT to a category 2A recommendation for PD-L1–negative, diffuse-type disease.
At IDWeek 2026, IDSA and HIVMA leaders and clinician advocates outline how stories, relationships, and bipartisan outreach shape ID and HIV policy.
At IDWeek 2026, Atul Gawande, MD, MPH, said USAID cuts are costing lives but that the field is "not back at square one."
About 9% of adults hospitalized with RSV died in the hospital or within 30 days of discharge, according to preliminary data presented at IDWeek 2026.
Hiddo Heerspink, PhD, discusses finerenone data in type 1 diabetes, FSGS and IgA nephropathy, and open questions on sequencing CKD therapies.
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
Real-World AMKD Data Highlight Quick Progression, Unmet Needs
3
Pulmonary Embolism Can Affect Elite Athletes, Too: Samantha Pettigrew, MD
4
Insurance Barriers Tied to Missed Long-Acting PrEP Starts
5